Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group’s subsidiary Zhuhai Livzon Microsphere Technology has received approval from China’s National Medical Products Administration to begin clinical trials of its independently developed Brexpiprazole Microspheres for Injection for adult schizophrenia. The long-acting, once-monthly sustained-release formulation is positioned as a next-generation treatment designed to improve medication adherence and reduce relapse risk, addressing a key clinical gap as no brexpiprazole long-acting product is yet approved in China.
The company has invested about RMB 7.53 million in developing the modified new chemical drug, which leverages brexpiprazole’s partial agonist and antagonist receptor profile and claims safety advantages over peers in its class. While the approval to start trials could strengthen Livzon’s role in psychiatric therapeutics and differentiate it in the domestic market, the drug must still successfully complete clinical studies and secure further regulatory clearance before it can be manufactured and sold, leaving development and approval risks for investors and other stakeholders.
The most recent analyst rating on (HK:1513) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company active in the research, development and manufacturing of innovative drugs, with a focus on microsphere sustained-release technologies through its wholly owned subsidiary Zhuhai Livzon Microsphere Technology Co., Ltd. The group targets central nervous system and psychiatric indications among other therapeutic areas, aiming to expand its presence in advanced drug-delivery formulations.
Average Trading Volume: 773,968
Technical Sentiment Signal: Hold
Current Market Cap: HK$30.28B
For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.